Charles D Pusey

List of Publications by Year
in descending order

148 papers	12,816 citations	41344 49 h-index	23533 111 g-index
173 all docs	173 docs citations	173 times ranked	6859 citing authors

#	Article	IF	Citations
1	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine, 2003, 349, 36-44.	27.0	1,239
2	Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis. Journal of the American Society of Nephrology: JASN, 2007, 18, 2180-2188.	6.1	973
3	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	27.0	820
4	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.9	719
5	Histopathologic Classification of ANCA-Associated Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2010, 21, 1628-1636.	6.1	681
6	Bone marrow contributes to renal parenchymal turnover and regeneration. Journal of Pathology, 2001, 195, 229-235.	4.5	607
7	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). American Journal of Clinical Pathology, 1999, 111, 507-513.	0.7	539
8	Long-Term Outcome of Antiâ€“Glomerular Basement Membrane Antibody Disease Treated with Plasma Exchange and Immunosuppression. Annals of Internal Medicine, 2001, 134, 1033.	3.9	503
9	Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. American Journal of Kidney Diseases, 2003, 41, 776-784.	1.9	435
10	Prospective Study of TNFÎ± Blockade with Infliximab in Anti-Neutrophil Cytoplasmic Antibody-Associated Systemic Vasculitis. Journal of the American Society of Nephrology: JASN, 2004, 15, 717-721.	6.1	345
11	Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney International, 1991, 40, 757-763.	5.2	314
12	Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney International, 2004, 66, 1535-1540.	5.2	284
13	Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1162-1172.	4.5	259
14	Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood, 2005, 106, 2050-2058.	1.4	246
15	Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2010, 25, 2209-2217.	0.7	200
16	Anti-glomerular basement membrane disease. Kidney International, 2003, 64, 1535-1550.	5.2	187
17	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. American Journal of Clinical Pathology, 2003, 120, 312-318.	0.7	167
18	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. Journal of Clinical Investigation, 2000, 105, 643-651.	8.2	158

#	Article	IF	Citations
19	Goodpasture's disease. Lancet, The, 2001, 358, 917-920.	13.7	155
20	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival,Âfrequency of relapse, and outcomes compared to single-seropositive patients. Kidney International, 2017, 92, 693-702.	5.2	154
21	Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. American Journal of Kidney Diseases, 2002, 39, 1162-1167.	1.9	143
22	Drug Insight: rituximab in renal disease and transplantation. Nature Clinical Practice Nephrology, 2006, 2, 221-230.	2.0	114
23	Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney International, 1997, 51, 222-229.	5.2	104
24	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney International, 2003, 64, 1685-1694.	5.2	102
25	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.	1.9	102
26	Therapeutic Effect of Antiâ€“TNF-Î± Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibodyâ€“Associated Systemic Vasculitis. Journal of the American Society of Nephrology: JASN, 2006, 17, 160-169.	6.1	98
27	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2019, 34, 63-73.	0.7	96
28	Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrology Dialysis Transplantation, 2004, 19, 2761-2768.	0.7	94
29	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrology Dialysis Transplantation, 2015, 30, 1185-1192.	0.7	94
30	Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factorâ€Î±. Nephrology Dialysis Transplantation, 2001, 16, 518-524.	0.7	89
31	Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney International, 2013, 83, 1150-1158.	5.2	86
32	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases. American Journal of Clinical Pathology, 2003, 120, 312-318.	0.7	86
33	Accelerated Nephrotoxic Nephritis Is Exacerbated in C1q-Deficient Mice. Journal of Immunology, 2001, 166, 6820-6828.	0.8	83
34	A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. Autoimmunity Reviews, 2016, 15, 577-584.	5.8	82
35	Anti-CD8 Monoclonal Antibody Therapy Is Effective in the Prevention and Treatment of Experimental Autoimmune Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2002, 13, 359-369.	6.1	81
36	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	5.8	79

#	Article	IF	Citations
37	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1128-1135.	4.5	75
38	Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. Kidney International, 2018, 94, 139-149.	5.2	73
39	In Goodpasture's Disease, CD4+ T Cells Escape Thymic Deletion and Are Reactive with the Autoantigen Î±3(IV)NC1. Journal of the American Society of Nephrology: JASN, 2001, 12, 1908-1915.	6.1	72
40	Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 63-72.	4.5	72
41	Plasma Immunoreactive Leptin Concentration in End-Stage Renal Disease. Clinical Science, 1997, 93, 119-126.	4.3	63
42	Is There a Role for TNF-Î± in Anti-Neutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis? Lessons from Other Chronic Inflammatory Diseases. Journal of the American Society of Nephrology: JASN, 2006, 17, 1243-1252.	6.1	61
43	Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2014, 53, 1693-1703.	1.9	59
44	Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2011, 26, 3280-3286.	0.7	58
45	Crescentic Glomerulonephritis: New Aspects of Pathogenesis. Seminars in Nephrology, 2011, 31, 361-368.	1.6	55
46	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic featuresÂonÂrenal biopsy. Kidney International, 2017, 92, 1223-1231.	5.2	55
47	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1571-1576.	4.5	53
48	Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 1262-1268.	5.2	53
49	Clinical and Imaging Features Predictive of Orbital Granulomatosis with Polyangiitis and the Risk of Systemic Involvement. Ophthalmology, 2014, 121, 1304-1309.	5.2	52
50	Spleen Tyrosine Kinase Inhibition Attenuates Autoantibody Production and Reverses Experimental Autoimmune GN. Journal of the American Society of Nephrology: JASN, 2014, 25, 2291-2302.	6.1	46
51	Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney International, 1999, 55, 1319-1326.	5.2	45
52	Expression and characterization of recombinant rat Î±3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. Nephrology Dialysis Transplantation, 2001, 16, 253-253.	0.7	43
53	Plasmapheresis in Immunologic Renal Disease. Blood Purification, 2012, 33, 190-198.	1.8	43
54	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology, 2020, 59, e24-e32.	1.9	42

#	Article	IF	Citations
55	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ, The, 2022, 376, e064604.	6.0	42
56	Oral Administration of Glomerular Basement Membrane Prevents the Development of Experimental Autoimmune Glomerulonephritis in the WKY Rat. Journal of the American Society of Nephrology: JASN, 2001, 12, 61-70.	6.1	39
57	High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. Journal of Rheumatology, 2019, 46, 285-293.	2.0	38
58	Management of ANCA-associated vasculitis: Current trends and future prospects. Therapeutics and Clinical Risk Management, 2010, 6, 253.	2.0	37
59	Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. Journal of Immunology, 2015, 195, 2343-2352.	0.8	37
60	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. CKJ: Clinical Kidney Journal, 2017, 10, sfw116.	2.9	37
61	S100A8/A9 (Calprotectin) Is Critical for Development of Glomerulonephritis and Promotes Inflammatory Leukocyteâ€“Renal Cell Interactions. American Journal of Pathology, 2015, 185, 1264-1274.	3.8	36
62	Treatment with an Antibody to VLA-1 Integrin Reduces Glomerular and Tubulointerstitial Scarring in a Rat Model of Crescentic Glomerulonephritis. American Journal of Pathology, 2002, 161, 1265-1272.	3.8	35
63	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney International, 2015, 88, 52-60.	5.2	34
64	Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology, 2016, 55, 1437-1442.	1.9	34
65	The role of monocytes in ANCA-associated vasculitides. Autoimmunity Reviews, 2016, 15, 1046-1053.	5.8	34
66	Spleen tyrosine kinase inhibition is an effectiveÂtreatment for established vasculitis inÂaÂpre-clinical model. Kidney International, 2020, 97, 1196-1207.	5.2	34
67	Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrology Dialysis Transplantation, 2017, 32, i123-i128.	0.7	33
68	Immunology of anti-glomerular basement membrane disease. Current Opinion in Nephrology and Hypertension, 2002, 11, 279-286.	2.0	32
69	Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology, 2015, 54, 899-907.	1.9	29
70	Macrophage Epoxygenase Determines a Profibrotic Transcriptome Signature. Journal of Immunology, 2015, 194, 4705-4716.	0.8	28
71	Interleukin-11 Attenuates Nephrotoxic Nephritis in Wistar Kyoto Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 2310-2320.	6.1	28
72	IgA1 Glycosylation Is Heritable in Healthy Twins. Journal of the American Society of Nephrology: JASN, 2017, 28, 64-68.	6.1	27

#	Article	IF	Citations
73	Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrology Dialysis Transplantation, 2012, 27, 1343-1350.	0.7	26
74	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney International, 2021, 100, 1316-1324.	5.2	26
75	Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management. Nephrology, 2005, 10, 368-376.	1.6	24
76	Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. Nephrology Dialysis Transplantation, 2014, 29, 1350-1361.	0.7	24
77	Segregation of Experimental Autoimmune Glomerulonephritis as a Complex Genetic Trait and Exclusion of <i>Col4a3</i> as a Candidate Gene. Nephron Experimental Nephrology, 2002, 10, 402-407.	2.2	23
78	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibodyâ€“associated small vessel vasculitis. Kidney International, 2015, 87, 807-811.	5.2	23
79	Antiglomerular Basement Membrane Disease. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 494-503.	2.1	21
80	ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. PLoS ONE, 2016, 11, e0165402.	2.5	21
81	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology, 2021, 60, 4654-4661.	1.9	20
82	Clinical and Imaging Features of Lacrimal Gland Involvement in Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 2125-2129.	5.2	19
83	Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome. Stem Cells and Development, 2016, 25, 395-404.	2.1	18
84	Is there a role for TNFÎ± blockade in ANCA-associated vasculitis and glomerulonephritis?. Nephrology Dialysis Transplantation, 2017, 32, i80-i88.	0.7	17
85	TESTING Corticosteroids in IgA Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 158-160.	4.5	16
86	Membranous Glomerulonephritis WithÂCrescents. Kidney International Reports, 2019, 4, 1577-1584.	0.8	16
87	A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. Journal of the Endocrine Society, 2020, 4, bvaa048.	0.2	16
88	Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by â€˜autoantigen complementarityâ€™. Journal of Autoimmunity, 2015, 59, 8-18.	6.5	14
89	Membranous nephropathy associated with viral infection. CKJ: Clinical Kidney Journal, 2021, 14, 876-883.	2.9	14
90	Repeated Membrane Plasma Separation with Onâ€Line Sorbent Treatment of Plasma in the Conscious Rat. Artificial Organs, 1986, 10, 135-144.	1.9	13

#	Article	IF	Citations
91	Genetic Susceptibility to Experimental Autoimmune Glomerulonephritis in the Wistar Kyoto Rat. American Journal of Pathology, 2012, 180, 1843-1851.	3.8	13
92	Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1324-1326.	4.5	13
93	Plasmapheresis in Antineutrophil Cytoplasmic Antibodiesâ€Associated Systemic Vasculitis. Therapeutic Apheresis and Dialysis, 2001, 5, 176-181.	0.6	12
94	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. Rheumatology, 2015, 54, 1025-1032.	1.9	12
95	The natural history of immunoglobulin M nephropathy in adults. Nephrology Dialysis Transplantation, 2017, 32, gfw063.	0.7	12
96	The Histopathological Classification of ANCA-associated Glomerulonephritis Comes of Age. Journal of Rheumatology, 2017, 44, 265-267.	2.0	12
97	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. Journal of Clinical Apheresis, 2018, 33, 638-644.	1.3	12
98	Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. F1000Research, 2018, 7, 1113.	1.6	12
99	B-cell-targeted therapy in adult glomerulonephritis. Expert Opinion on Biological Therapy, 2013, 13, 1691-1706.	3.1	11
100	Local IL-17 Production Exerts a Protective Role in Murine Experimental Glomerulonephritis. PLoS ONE, 2015, 10, e0136238.	2.5	11
101	Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background. Scientific Reports, 2019, 9, 20398.	3.3	11
102	A Comparison of Pulsatile Hypothermic and Normothermic Ex Vivo Machine Perfusion in a Porcine Kidney Model. Transplantation, 2021, 105, 1760-1770.	1.0	10
103	Multisorbent Plasma Perfusion in Fulminant Hepatic Failure: Effects of Duration and Frequency of Treatment in Rats with Grade III Hepatic Coma. Artificial Organs, 2001, 25, 109-118.	1.9	9
104	Tissue Interleukin-17 and Interleukin-23 as Biomarkers for Orbital Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 2140-2142.	5.2	9
105	Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. Scientific Reports, 2018, 8, 53.	3.3	9
106	Plasma exchange in anti-glomerular basement membrane disease. Presse Medicale, 2019, 48, 328-337.	1.9	9
107	Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. Kidney International, 2021, 99, 488-489.	5.2	8
108	Ocular manifestations of Wegenerâ€™s granulomatosis. Expert Review of Ophthalmology, 2011, 6, 541-555.	0.6	7

#	Article	IF	Citations
109	Issues in trial design for ANCA-associated and large-vessel vasculitis. Nature Reviews Rheumatology, 2014, 10, 502-510.	8.0	7
110	Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity. CKJ: Clinical Kidney Journal, 2016, 9, 429-431.	2.9	7
111	Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. Rheumatology, 2021, , .	1.9	7
112	Rituximab for maintenance of remission in AAV. Nature Reviews Nephrology, 2015, 11, 131-132.	9.6	6
113	Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. BMC Nephrology, 2019, 20, 352.	1.8	6
114	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). Kidney International Reports, 2019, 4, 1342-1348.	0.8	6
115	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. Nephrology Dialysis Transplantation, 2021, 36, 739-742.	0.7	6
116	The Continuing Challenge of Anti-Neutrophil Cytoplasm Antibodyâ€“Associated Systemic Vasculitis and Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1221-1223.	6.1	5
117	Renal & Ocular Targets for Therapy in Wegeners Granulomatosis. Inflammation and Allergy: Drug Targets, 2009, 8, 70-79.	1.8	5
118	The heterogeneous mononuclear phagocyte system of the kidney. Kidney International, 2014, 85, 1011-1014.	5.2	5
119	CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. BMC Nephrology, 2016, 17, 139.	1.8	5
120	Crescentic glomerulonephritis: beyond the immune system. Nature Reviews Nephrology, 2017, 13, 198-200.	9.6	5
121	Nasal reconstructive surgery for vasculitis affecting the nose: our two-centre international experience. European Archives of Oto-Rhino-Laryngology, 2020, 277, 3059-3066.	1.6	5
122	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelinesâ€"Executive summary. Rheumatology, 2020, 59, 727-731.	1.9	5
123	A novel model of nephrotic syndrome results from a point mutation in Lama5 and is modified by genetic background. Kidney International, 2022, 101, 527-540.	5.2	5
124	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization. Scientific Reports, 2022, 12, 3330.	3.3	5
125	Ocular manifestations of Wegenerâ€™s granulomatosis. Expert Review of Ophthalmology, 2007, 2, 91-103.	0.6	4
126	Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. Current Treatment Options in Rheumatology, 2020, 6, 313-324.	1.4	4

#	Article	IF	Citations
127	Characterisation of an enhanced preclinical model of experimental MPOâ€ANCA autoimmune vasculitis. Journal of Pathology, 2021, 255, 107-119.	4.5	4
128	Cellular aspects of vasculitis â€" T cell-mediated aspects. Seminars in Immunopathology, 2001, 23, 287-298.	4.0	3
129	L46. Novel forms of clinical vasculitis: Anti-GBM vasculitis (Goodpasture's disease). Presse Medicale, 2013, 42, 625-628.	1.9	3
130	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 2018, 94, 926-936.	5.2	3
131	Glomerulonephritis and autoimmune vasculitis are independent of <scp>P2RX7</scp> but may depend on alternative inflammasome pathways. Journal of Pathology, 2022, 257, 300-313.	4.5	3
132	Peroxidasinâ€"a Novel Autoantigen in Anti-GBM Disease?. Journal of the American Society of Nephrology: JASN, 2018, 29, 2605.2-2607.	6.1	2
133	Immunomodulatory Properties of Mesenchymal Stromal Cells Can Vary in Genetically Modified Rats. International Journal of Molecular Sciences, 2021, 22, 1181.	4.1	2
134	The authors reply:. Kidney International, 2022, 101, 648-649.	5.2	2
135	Succinylated gelatin as partial fluid replacement in chronic therapeutic plasma exchange. Journal of Clinical Apheresis, 1992, 7, 124-125.	1.3	0
136	T cell responses in ANCA-positive vasculitis. Nephrology, 1997, 3, s778-s779.	1.6	0
137	Regulation of inflammation and scarring in glomerulonephritis. International Journal of Experimental Pathology, 2008, 85, A14-A14.	1.3	0
138	Kallikreins: unravelling the genetics of autoimmune glomerulonephritis*. Nephrology Dialysis Transplantation, 2009, 24, 2987-2989.	0.7	0
139	Goodpasture Syndrome and Other Antiglomerular Basement Membrane Diseases. , 2014, , 193-197.		0
140	SURVEY OF STAFF OPINIONS ABOUT EXTENDED HAEMODIALYSIS TREATMENT TIME AND SERVICE IMPLICATIONS. Journal of Renal Care, 2015, 41, 162-167.	1.2	0
141	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2015, 30, iii317-iii317.	0.7	0
142	220.â€ƒDEFINING THE PATHOGENESIS OF ANCA AND ANTI-GBM DOUBLE POSITIVITY. Rheumatology, 2019, 58, .	1.9	0
143	260.â€ƒLONG TERM OUTCOMES OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS PRESENTING WITH SEVERE RENAL DYSFUNCTION. Rheumatology, 2019, 58, .	1.9	0
144	Dr. Kang, et al, reply. Journal of Rheumatology, 2019, 46, 1244.2-1244.	2.0	0

#	Article	IF	Citations
145	Dr. Kang, et al reply. Journal of Rheumatology, 2019, 46, 866.2-867.	2.0	0
146	MO004THE SAFETY PROFILE OF REPEAT RITUXIMAB TREATMENT IN ANCA-ASSOCIATED VASCULITIS - A 10 YEAR SINGLE CENTRE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
147	New Insights into Epidemiology and Outcome of Bacterial Infectionâ€“Related Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1149-1151.	4.5	0
148	Goodpastureâ€™s Syndrome and Other Antiâ€“Glomerular Basement Membrane Disease. , 2009, , 186-190.		0